Core Laboratories posts Q4 2025 results, sets dividend

Core Laboratories Inc. filed a current report stating it issued a press release with its financial results for the fourth quarter of 2025 and the year ended December 31, 2025.

Rhea-AI Filing Summary

Core Laboratories Inc. filed a current report stating it issued a press release with its financial results for the fourth quarter of 2025 and the year ended December 31, 2025. The company also announced a quarterly cash dividend of $0.01 per share of common stock.

The dividend will be paid on March 9, 2026 to shareholders of record on February 16, 2026. The related press release is furnished as an exhibit and is not treated as filed or incorporated by reference into other securities law filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Core Laboratories Inc. (CLB) announce in its latest 8-K?

Core Laboratories Inc. reported that it issued a press release with financial results for the fourth quarter of 2025 and the full year 2025. The company also announced a quarterly cash dividend of $0.01 per share for its common stock, with specific record and payment dates.

What dividend did Core Laboratories Inc. (CLB) declare and when will it be paid?

Core Laboratories Inc. declared a quarterly cash dividend of $0.01 per share of common stock. The dividend will be paid on March 9, 2026 to shareholders of record on February 16, 2026, providing a scheduled cash return to eligible shareholders on that payment date.

Which period’s financial results did Core Laboratories Inc. (CLB) discuss?

Core Laboratories Inc. announced financial results for the fourth quarter of 2025 and for the year ended December 31, 2025. These results were communicated through a press release referenced in the filing and attached as an exhibit for investors seeking detailed financial information.

How is the Core Laboratories Inc. (CLB) press release treated under securities laws?

The press release referenced by Core Laboratories Inc. is treated as furnished, not filed, under the Securities Exchange Act. It is not automatically incorporated by reference into other Securities Act or Exchange Act filings unless another document expressly states such incorporation.

Where can investors find more details on Core Laboratories Inc. (CLB) Q4 2025 results?

Investors can review detailed figures for Core Laboratories Inc.’s fourth quarter 2025 and full-year 2025 results in the press release attached as Exhibit 99.1. The 8-K notes that this exhibit contains the complete financial information and related commentary.

What is the record date for Core Laboratories Inc. (CLB) Q1 2026 dividend?

The record date for Core Laboratories Inc.’s $0.01 per share quarterly cash dividend is February 16, 2026. Shareholders listed as of that date will be eligible to receive the dividend payment scheduled for March 9, 2026, according to the company’s disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:58 PM EST Learn about SEC filing dates

0001958086false00019580862026-02-042026-02-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41695	98-1164194
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
6316 Windfern Road
Houston, TX		77040
(Address of principal executive offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (713) 328-2673

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock (par value $0.01)		CLB		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 4, 2026, Core Laboratories Inc. issued a press release announcing its financial results for the fourth quarter of 2025 and year ending December 31, 2025.

Item 7.01 Regulation FD Disclosure.

On February 4, 2026, Core Laboratories Inc. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on February 16, 2026 and payable March 9, 2026.

The full text of the press release is set forth in Exhibit 99.1 attached hereto.

The information in this Report and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued on February 4, 2026 *

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

* This exhibit is intended to be furnished and shall not be deemed “filed” for purposes of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Core Laboratories Inc.
Dated: February 4, 2026		By		/s/ Christopher S. Hill
				Christopher S. Hill
				Chief Financial Officer